CSLCSLLY -1.55%73 EV-to-OCF is 40.28 as of Jul. 12, 2026, which is 8% above its 10-year median of 37.22. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.59 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,411 Biotechnology companies, CSL ranks worse than 93.83% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, CSL's Enterprise Value is $52,449 Mil.
CSL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1,302 Mil. Therefore, CSL's EV-to-OCF for today is 40.28.
The historical rank and industry rank for CSL's EV-to-OCF or its related term are showing as below:
CSLLY'
s EV-to-OCF Range Over the Past 10 Years
Min: 11.8 Med: 37.22 Max: 66.99
Current: 38.82
During the past 13 years, the highest EV-to-OCF of CSL was 66.99. The lowest was 11.80. And the median was 37.22.
CSLLY's EV-to-OCF is ranked worse than 93.83% of 1411
companies
in the Biotechnology industry
Industry Median: -3.51
vs CSLLY: 38.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-12), CSL's stock price is $21.61.
CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.205. Therefore, CSL's PE Ratio (TTM) for today is 105.41.
CSL (OTCPK:CSLLY) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CSL's share price for today is $21.61.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.205.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CSL EV-to-OCF Related Terms
CSL EV-to-OCF Historical Data
* Premium members only.
The historical data trend for CSL's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where CSL's EV-to-OCF falls into.
CSL's current Enterprise Value is $52,449 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1,302 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a EV-to-OCF of 40.28 as of Jul. 12, 2026. This is near median its historical median of 37.22. Over the past decade, CSL's EV-to-OCF has ranged from 11.80 to 66.99. According to the industry distribution chart, CSL ranks #1324 out of 1411 companies in the Biotechnology industry, placing it in the top 93.8%.
Is CSL's EV-to-OCF too high?
CSL's current EV-to-OCF of 40.28 is near median its 10-year median of 37.22. Over the past 10 years, this metric has ranged from a low of 11.80 to a high of 66.99. Based on the distribution chart, CSL ranks #1324 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #1324 out of 1411 companies for EV-to-OCF. This places CSL in the lower half of its industry. Historically, CSL's own EV-to-OCF has ranged from 11.80 to 66.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. CSL's current EV-to-OCF is 40.28, which is near median its own 10-year median of 37.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.59, compared to a current price of $21.61 — trading 57.3% below its estimated fair value. The current EV-to-OCF is 40.28, which is near median its 10-year median of 37.22. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CSL (CSLLY), the current EV-to-OCF is 40.28 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.61 is trading 57.3% below its estimated GF Value™ of $50.59.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
EV-to-OCF: 40.28 (near median its 10-year median of 37.22)
GF Value™: $50.59 vs. price of $21.61 (57.3% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
